Abstract | BACKGROUND: METHOD: Patients with DSM-IV PTSD who were stable on current medications and still symptomatic were eligible for inclusion in this open-label case series. Tiagabine was initiated at 2 mg nightly and increased by 2-mg increments every 2 to 3 days until an optimal response was achieved. The Clinical Global Impressions-Improvement scale and PTSD Checklist-Civilian Version (PCL-C) were used to evaluate changes in PTSD symptoms. RESULTS: Seven consecutive female patients were identified as eligible. Tiagabine markedly improved PTSD symptoms within 2 weeks for 6 of the 7 patients, and 6 patients were rated as "much improved" or "very much improved." The mean PCL-C score was significantly reduced at weeks 2 and 8 (p <.05) as were the 3 PCL-C subscales and 1 of 2 items related to sleep disturbance. The mean effective daily dosage was approximately 8 mg (range, 4-12 mg/day). Treatment with tiagabine was generally well tolerated. CONCLUSIONS: These preliminary open-label findings suggest that the selective GABA reuptake inhibitor tiagabine may be a promising therapeutic option in the treatment of PTSD. Further study into the efficacy and safety of tiagabine for the treatment of PTSD is warranted.
|
Authors | Fletcher B Taylor |
Journal | The Journal of clinical psychiatry
(J Clin Psychiatry)
Vol. 64
Issue 12
Pg. 1421-5
(Dec 2003)
ISSN: 0160-6689 [Print] United States |
PMID | 14728102
(Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antidepressive Agents
- GABA Agonists
- Nipecotic Acids
- Tiagabine
|
Topics |
- Adult
- Antidepressive Agents
(administration & dosage, therapeutic use)
- Comorbidity
- Depressive Disorder, Major
(diagnosis, drug therapy, psychology)
- Drug Therapy, Combination
- Female
- GABA Agonists
(adverse effects, therapeutic use)
- Humans
- Middle Aged
- Nipecotic Acids
(adverse effects, therapeutic use)
- Stress Disorders, Post-Traumatic
(diagnosis, drug therapy, psychology)
- Tiagabine
- Treatment Outcome
|